Leerink Partners Initiates Coverage On Regulus Therapeutics With Outperform Rating, Announces Price Target of $6
Leerink Partners Initiates Coverage On Regulus Therapeutics With Outperform Rating, Announces Price Target of $6
Leerink Partners以跑贏大盤的評級啓動了對Regulus Therapeutics的報道，宣佈目標股價爲6美元
Leerink Partners analyst Joseph Schwartz initiates coverage on Regulus Therapeutics (NASDAQ:RGLS) with a Outperform rating and announces Price Target of $6.
Leerink Partners分析師約瑟夫·施瓦茨以跑贏大盤的評級開始對Regulus Therapeutics（納斯達克股票代碼：RGLS）進行報道，並宣佈目標股價爲6美元。